You are here

Revised Labeling for Aranesp, Epogen, and Procrit Provides Updated Safety Information About Pure Red Cell Aplasia and Severe Anemia

December 1, 2005 -- ROCKVILLE, MD -- Amgen, Ortho Biotech and FDA notified healthcare professionals of revision to the Warnings, Precautions, Adverse Reactions, and Dosage and Administration sections of the prescribing information for these three products. The revised labeling provides updated safety information on reports of pure red cell aplasia and severe anemia, with or without other cytopenias, associated with neutralizing antibodies to erythropoietin in patients treated with these products. This has been reported predominantly in patients with CRF receiving these products by subcutaneous administration. Recommendations for evaluation and treatment are provided in the new prescribing information.

Read the complete MedWatch 2005 Safety summary, including links to the Dear Healthcare Professional letters and revised prescribing information at:

https://www.fda.gov/safety/medical-product-safety-information/medwatch-safety-alerts-human-medical-products

and

https://www.fda.gov/safety/medical-product-safety-information/medwatch-safety-alerts-human-medical-products.

Source: The Food and Drug Administration

Recent Headlines

Company says it is offering a more affordable generic to the agent used to treat varicose veins
Company, FDA held a meeting to discuss trials in bunion, "tummy tuck" patients
New model uses piezoelectric material used in microphones and high-end speakers
Rozanolixizumab touted as possible alternative to standard therapy of corticosteroids, intravenous immunoglobulin
Intrauterine environment may have a 'programming effect' on fetal heart
Heart rate variability may pinpoint who will benefit
Researchers found that ECMO before transplant tripled chance of a long hospital stay